Fig. 3From: Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong KongTornado Diagram for the ICER of pembrolizumab vs. DTIC. (a) The vertical line in the middle indicates the ICER of the base-case scenario ($35,993). (b) The orange bar indicates the ICER result when the minimum value of the input is used, while the blue bar indicates the ICER result when that maximum value of the input is usedBack to article page